Concepedia

David van Veenhuyzen

DV

4

Publications

488

Citations

4

H-Index

2010

Active since

Affiliations

Shionogi (United States)(Current)

Shionogi (Japan)

David van Veenhuyzen is an author at Shionogi (United States) specializing in urology, sepsis, and antimicrobial resistance.

Top concepts

Publications per year

2010–2018

4

Publications

4

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · The Lancet Infectious Diseases · 2018 · 387 citations

, , +10

Update on the Cardiac Safety of Moxifloxacin

Wilhelm Haverkamp, Frank Kruesmann, Anna Fritsch et al. · Current Drug Safety · 2012 · 44 citations · Full text

Moxifloxacin five‐day therapy versus placebo in acute bacterial rhinosinusitis

James A. Hadley, Ralph Mösges, Martin Desrosiers et al. · The Laryngoscope · 2010 · 31 citations

Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI)

Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · Open Forum Infectious Diseases · 2017 · 26 citations · Full text

, , +17

Rows per page

1–4 of 4